European Commission approves OMP Designation for NLX-112 (befiradol) following compelling results in studies funded by the US Dept of De ...

CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing ...

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

The novel agent LP-184 has been granted rare pediatric disease designations in malignant rhabdoid tumors, rhabdomyosarcoma, ...

The U.S. Food and Drug Administration approved IntraBio's drug for a rare and fatal genetic disorder, the health regulator ...

A rare cause of hereditary cognitive decline known as CSF1R-Related Disorder (CSF1R-RD) gets its name from mutations in the ...

Miplyffa treats Niemann-Pick disease type C, which progressively impacts the abilities to speak, swallow, and walk or move ...

Children's Hospital of Michigan is treating the first person in Michigan with a newly approved gene-editing therapy for beta thalassemia.

Zirconium can be eas Through the Collaboration with U.S. Department of Energy and Virginia Tech, ARR presents positive results from a metallurgical leaching study on extraction of Rare Earth ...

Early diagnosis of type 1 diabetes was associated with superior long-term glycemic control and insulin requirements among children.